<DOC>
	<DOCNO>NCT02022904</DOCNO>
	<brief_summary>This minimal risk correlative clinical blood-drawing protocol . The objective lead pilot component determine whether Circulating Tumor Cells ( CTC 's ) capture use novel mesenchymal-marker base Near Infrared-Emissive Polymersomes ( NIR-EPs ) , PSMA-based NIR-EP , epithelial EpCAM-based NIR-EP . If successful , capture method evaluate large comparative study .</brief_summary>
	<brief_title>Prostate Cancer Circulating Tumor Cells Based Epithelial-Mesenchymal Transition Biology</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplastic Cells , Circulating</mesh_term>
	<criteria>histologically confirm diagnosis adenocarcinoma prostate Clinical radiographic evidence metastatic disease Evidence disease progression androgen deprivation therapy ( ADT ) evidence either follow past : 1 . Two consecutive PSA level great PSA nadir achieve ADT , separate great one week 2 . Radiographic evidence disease progression define new bone scan lesion soft tissue/visceral metastasis &gt; 2 cm diameter . 3 . Clinical progression determine treat physician . Age great 18 year . Ability understand willingness sign write informed consent document History intercurrent past medical psychiatric illness would make participation blood draw protocol difficult feasible discretion principal investigator coinvestigator ( )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>castrate resistant</keyword>
</DOC>